DURHAM, N.C., Oct. 17, 2023 /PRNewswire/ -- Ten63 Therapeutics, a company combining generative AI and physics-based models to develop first- and best-in-class therapeutics with an internal pipeline focused on oncology, is pleased to announce its partnership with newly unveiled cancer-focused venture fund, Yosemite.

DURHAM，N.C.，2023年10月17日/PRNewswire/-Ten63 Therapeutics，一家将生成AI和基于物理的模型相结合的公司，开发一流和一流的治疗方法，内部管道专注于肿瘤学，很高兴宣布与新推出的以癌症为中心的风险投资基金Yosemite合作。

Prior to launch, the Yosemite team co-led Ten63's oversubscribed Series A financing with Hatteras Venture Partners. Led by Reed Jobs, Yosemite is focused on making cancer non-lethal within our lifetime..

在推出之前，Yosemite团队与Hatteras Venture Partners共同领导Ten63的超额发行的A系列融资。在里德·约伯斯的领导下，约瑟米专注于在我们的一生中使癌症不致命。。

Continue Reading

继续阅读

Dr. Beverly Lu, investor at Yosemite and board director at Ten63 Therapeutics.

Yosemite的投资者Beverly Lu博士和Ten63 Therapeutics的董事会董事。

In connection with the partnership, Yosemite's Dr. Beverly Lu joined the company's board of directors. Trained in both chemistry and immune-oncology at UC Berkeley, Caltech and Harvard, Dr. Lu's career spans nearly 2 decades of experience as an investor, scientist, global consultant and director at Yosemite, Emerson Collective, McKinsey and Amgen.

与合作伙伴关系有关，Yosemite的Beverly Lu博士加入了该公司的董事会。在加州大学伯克利分校，加州理工学院和哈佛大学接受化学和免疫肿瘤学方面的培训，卢博士的职业生涯跨越了近20年的投资者，科学家，全球顾问以及Yosemite，Emerson Collection，McKinsey和Amgen的董事经验。

'Dr. Lu brings a deep strategic and operational understanding of the biotech and pharma ecosystem to the company,' said Chairman of Ten63's Board, Clay Thorp, General Partner of Hatteras Venture Partners..

'Dr。Ten63董事会主席Clay Thorp（Hatteras Venture Partners的总合作伙伴）表示，Lu为公司带来了对生物技术和制药生态系统的深刻战略和运营理解。。

'Ten63 and Yosemite are deeply aligned in a shared mission to revolutionize outcomes for cancer patients. Reed Jobs, Dr. Beverly Lu, and the entire team at Yosemite have been a massive value-add along our path to bringing life-altering, first-and best- in class therapies to cancer patients' said Dr.

Ten63和Yosemite在共同的使命中深深地结合在一起，彻底改变癌症患者的预后。Reed Jobs博士，Beverly Lu博士以及Yosemite的整个团队在为癌症患者带来改变生活，一流和一流疗法的道路上增加了巨大的价值。

Marcel Frenkel, Ten63's CEO..

Marcel Frenkel，Ten63的首席执行官。。

'AI technologies will likely revolutionize the way we have been doing drug discovery in the past decades, providing solutions to devasting diseases such as cancer. We believe the highly differentiated technology platform and team at TEN63 will help improve the lives of cancer patients' Dr. Lu said.Dr.

“人工智能技术可能会彻底改变我们过去几十年来进行药物发现的方式，为贬值癌症等疾病提供解决方案。我们相信TEN63高度差异化的技术平台和团队将有助于改善癌症患者卢博士的生活。博士。

Lu serves on Ten63's board directors along with Dr. Frenkel, Clay Thorp, General Partner of Hatteras Venture Partners, Damien Petty, operating partner at Morpheus Ventures, and Dr. Steve Hall formerly from Lilly Ventures.About Ten63 Therapeutics, Inc.Ten63 is a Duke and TTIC spin-out headquartered in the Research Triangle in North Carolina, where it is currently expanding its chemistry and computational teams.

Lu是Ten63的董事会成员，还有Frenkel博士，Clay Thorp博士，Hatteras Venture Partners的一般合作伙伴，Damien Petty，Morpheus Ventures的运营合作伙伴，以及之前来自Lilly Ventures的Steve Hall博士。关于Ten63 Therapeutics，Inc.Ten63是Duke and TTIC spin-out总部设在北卡罗来纳州的Research Triangle，它目前正在扩大其化学和计算团队。

Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. The company is progressing an internal pipeline focused on oncology while pursuing select and strategic partnerships in multiple indications.About YosemiteYosemite partners with leading researchers and innovative entrepreneurs working to make cancer non-lethal within our lifetime.

Ten63正在利用其超越计算平台的生成化学来开发一流和一流的治疗方法。该公司正在开展一项专注于肿瘤学的内部管道，同时在多种适应症中寻求精选和战略合作伙伴关系。关于YosemiteYosemite合作伙伴与领先的研究人员和创新企业家一起努力使癌症在我们的一生中不致命。

The firm deploys capital from early non-profit grantees through late-stage companies to fund advancements across the oncology ecosystem aimed to meaningfully accelerate the technology, treatments, and standard of care to improve the lives of cancer patients.Regulatory Note: The entirety of Yosemite's portfolio is not represented above, and no assumption should be made that an investment in a Yosemite portfolio company will be profitable.

该公司从早期非营利受赠者到晚期公司部署资金，为整个肿瘤生态系统的进步提供资金，旨在有意义地加速技术，治疗和护理标准，以改善癌症患者的生活。监管说明：整个Yosemite的投资组合未在上面列出，不应假设对Yosemite投资组合公司的投资将有利可图。

Although no compensation was provided to the portfolio company for its comments about Yosemite, positive statements could be incentivized due to a company's ongoing relationship with Yosemite. Past performance is not indicative of.

尽管投资组合公司对Yosemite的评论没有提供任何补偿，但由于公司与Yosemite的持续关系，正面陈述可能会受到激励。过去的表现并不表示。